Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel ...
Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic ...
Basilea Pharmaceutica AG: Basilea is awarded additional CARB-X funding to develop new drug ...
Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc ...